Nanotechnology has generated tremendous hopes in recent years toward the design of advanced functional materials, especially in the bio-medical field. Nano-sized-materials such as magnetite nanoparticles display indeed fascinating physico-chemical properties that, if tuned properly, can be exploited to design new bio-diagnostic and therapeutic strategies as well as innovative biotechnology methodologies. Owing to their biocompatibility and excellent magnetic properties, magnetite nanocrystals have been the object of a tremendous amount of research in the last decade and numerous (bio)applications have been reported. Importantly, advances in the synthesis of magnetite nanoparticles enable excellent control over their size, shape, and composition. Despite these remarkable progresses, many issues remain to be overcome for these nanotechnology products to revolution the medical practice. The fine control and application of colloidal nanostructures such as magnetite nanoparticles in complex biological systems remains especially challenging. This article attempts to review the current status of magnetite nanoparticles preparation and use, with a special emphasis on bio-medical applications, but also to outline the promises and challenges associated to this emerging technology.

Diatom silica microcapsules prepared by purification of diatomaceous earth (DE) were functionalised by dopamine modified iron-oxide nanoparticles, in order to introduce diatoms with magnetic properties. The application of magnetised diatoms as magnetically guided drug delivery microcarriers has been demonstrated.

Recently, organ-on-a-chip models, which are microfluidic devices that mimic the cellular architecture and physiological environment of an organ, have been developed and extensively investigated. The chips can be tailored to accommodate the disease conditions pertaining to many organs; and in the case of this review, the lung. Lung-on-a-chip models result in a more accurate reflection compared to conventional in vitro models. Pharmaceutical drug testing methods traditionally use animal models in order to evaluate pharmacological and toxicological responses to a new agent. However, these responses do not directly reflect human physiological responses. In this review, current and future applications of the lung-on-a-chip in the respiratory system will be discussed. Furthermore, the limitations of current conventional in vitro models used for respiratory disease modeling and drug development will be addressed. Highlights of additional translational aspects of the lung-on-a-chip will be discussed in order to demonstrate the importance of this subject for medical research.